Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Themis Medicare Limited ( (IN:THEMISMED) ).
Themis Medicare’s board-appointed Preferential Issue Committee has approved the allotment of 4,595,795 convertible equity warrants to Vividhmargi Investments Private Limited on a preferential basis. The minimum issue price has been set at Rs 99.76 per warrant in line with SEBI regulations, effectively rounded to Rs 100, subject to shareholder and stock exchange approvals.
The company has also cleared the postal ballot process to seek shareholder consent, with e-voting scheduled from February 26 to March 27, 2026. The move signals a targeted capital-raising effort that could strengthen Themis Medicare’s balance sheet and strategic flexibility, while potentially bringing in a committed financial investor through the warrant conversion route.
More about Themis Medicare Limited
Themis Medicare Limited is an India-based pharmaceutical company engaged in manufacturing and marketing medicinal products. Operating from facilities in Gujarat and a corporate office in Mumbai, it focuses on formulations for the domestic market and supplies to regulated and semi-regulated international markets.
Average Trading Volume: 8,342
Technical Sentiment Signal: Sell
Current Market Cap: 7.87B INR
See more insights into THEMISMED stock on TipRanks’ Stock Analysis page.